Those who suffered similar injuries due to taking Ozempic may benefit from extensions while the class action is in process
However, these changes dont happen all at once
While symptomatic low blood pressure is not listed as a common adverse reaction in the SmPC, it may occur in some patients, particularly those taking concurrent antihypertensive medications or diuretics, or those experiencing dehydration due to gastrointestinal side effects
The absence of a significant eGFR change in our cohort likely reflects lower baseline kidney risk and the shorter observation period: baseline eGFR was ~ 76 ml/min/1.73 m 2 versus ~ 47 ml/min/1.73 m 2 in FLOW, and our follow-up was 1 or 2 years versus a median 3.4 years in FLOW, which may be insufficient to detect meaningful eGFR differences in earlier-stage T2D
The typical escalation looks like this: Weeks 1 through 4: 0.25 mg per week (adjustment phase, minimal visible effects) Weeks 5 through 8: 0.5 mg per week (appetite suppression becomes more consistent) Weeks 9 through 12: 1.0 mg per week (significant appetite reduction, weight loss accelerates) Weeks 13 through 16: 1.7 mg per week (strong effects for most users) Week 17 onward: 2.4 mg per week (full therapeutic dose) Each dose increase brings a noticeable step up in effect intensity
